Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Leanne Griffin

Physician Assistant Conway, AR Physician Assistant

NPI 1265635981 CMS profile 10994506

1014 Harkrider St Ste B, Conway, AR 72032

Open in the dashboard

General payments

$9,018

539 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leanne Griffin of Conway, AR is reported in the CMS Open Payments database as having received $9,018 across 539 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,793 99
2024 General $1,569 90
2023 General $1,827 109
2022 General $1,766 111
2021 General $2,063 130

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leanne Griffin
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Leanne Griffin were reported at $1,793. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Leanne Griffin Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,063 $132 $37–$438 $132
2022 $1,766 $155 $48–$522 $149
2023 $1,827 $167 $52–$557 $160
2024 $1,569 $178 $55–$600 $164
2025 $1,793 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,667 118 payments
  2. AstraZeneca Pharmaceuticals LP $1,092 49 payments
  3. Lilly USA, LLC $816 59 payments
  4. Amgen Inc. $678 37 payments
  5. Pfizer Inc. $669 45 payments
  6. Novo Nordisk Inc $600 35 payments
  7. GlaxoSmithKline, LLC. $353 22 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $318 17 payments
  9. Novartis Pharmaceuticals Corporation $267 17 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $266 12 payments
  11. Other $2,294 128 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,018 539 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $683 46 payments
  2. QULIPTA $627 29 payments
  3. BREZTRI $532 19 payments
  4. FARXIGA $510 17 payments
  5. AIRSUPRA $474 18 payments
  6. VRAYLAR $458 44 payments
  7. Ozempic $420 25 payments
  8. RYBELSUS $420 25 payments
  9. Otezla $396 23 payments
  10. NURTEC ODT $362 24 payments
  11. Other $7,739 467 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 77 drugs

Part D claims

2,553

Median for Physician Assistant: 241

Drug cost

$137,144

Median for Physician Assistant: $4,110

Branded share of claims

21.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 16 $18,041
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 23 $17,458
Trulicity Dulaglutide Brand 14 $15,033
Jardiance Empagliflozin Brand 11 $14,374
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 13 $13,744
Eliquis Apixaban Brand 14 $12,188
Linzess Linaclotide Brand 13 $9,104
Myrbetriq Mirabegron Brand 11 $7,721
Breo Ellipta Fluticasone/Vilanterol Brand 11 $4,231
Albuterol Sulfate Hfa Albuterol Sulfate Brand 50 $1,747

The 10 drugs with the highest cost, of 77 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$30,190

Of which drugs: $3,119

Medicare patients

237

Average age 73

Services billed

1,208

143 women, 94 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 48%
Arthritis 48%
Depression 45%
Diabetes 27%
Chronic kidney disease 24%
COPD 22%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 12 128 $11

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $140
$140 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $133
$133 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $125
$125 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $108
$108 23 —
ZAVZPRET
  • PFIZER INC. $108
$108 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

539 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record